-
公开(公告)号：US20170305932A1
公开(公告)日：2017-10-26
申请号：US15513357
申请日：2015-10-02
Applicant: UCB Biopharma SPRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07D495/18 , C07D487/18 , C07D491/18 , C07F7/18 , C07D513/18
CPC classification number: C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US20150203486A1
公开(公告)日：2015-07-23
申请号：US14414287
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Praful Tulshi Chovatia , Anne Marie Foley , Ellen Olivia Gallimore , Laura Jane Gleave , Alexander Heifetz , Helen Tracey Horsley , Martin Clive Hutchings , Victoria Elizabeth Jackson , James Andrew Johnson , Craig Johnstone , Boris Kroeplien , Fabien Claude Lecomte , Deborah Leigh , Martin Alexander Lowe , James Madden , John Robert Porter , Joanna Rachel Quincey , Laura Claire Reed , James Thomas Reuberson , Anthony John Richardson , Sarah Emily Richardson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: C07D471/04 , A61K31/496 , A61K31/506 , C07D491/107 , A61K31/5377 , A61K31/5513 , A61K31/554 , A61K31/437 , A61K31/541
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107 , C07D519/00
Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US10202405B2
公开(公告)日：2019-02-12
申请号：US15513357
申请日：2015-10-02
Applicant: UCB Biopharma SPRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US09550737B2
公开(公告)日：2017-01-24
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D401/04 , C07D401/14 , C07D403/04 , C07D491/107 , C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D405/06
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US20150152065A1
公开(公告)日：2015-06-04
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D235/12 , C07D401/04 , A61K31/4439 , A61K31/454 , C07D405/06 , A61K31/4192 , C07D403/04 , A61K31/4709 , A61K31/4725 , A61K31/444 , C07D401/14 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D491/107 , A61K31/506 , A61K31/4184
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
Patent Agency Ranking
公开(公告)号：US20160376276A1
公开(公告)日：2016-12-29
申请号：US15038818
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , A61K31/53
CPC classification number: C07D487/04 , A61K31/53 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14
Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列取代的式（I）咪唑并[1,2-b] [1,2,4]三嗪衍生物因此有益于治疗和/或预防各种人类疾病 ，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US09309243B2
公开(公告)日：2016-04-12
申请号：US14414287
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Praful Tulshi Chovatia , Anne Marie Foley , Ellen Olivia Gallimore , Laura Jane Gleave , Alexander Heifetz , Helen Tracey Horsley , Martin Clive Hutchings , Victoria Elizabeth Jackson , James Andrew Johnson , Craig Johnstone , Boris Kroeplien , Fabien Claude Lecomte , Deborah Leigh , Martin Alexander Lowe , James Madden , John Robert Porter , Joanna Rachel Quincey , Laura Claire Reed , James Thomas Reuberson , Anthony John Richardson , Sarah Emily Richardson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: C07D491/02 , C07D471/04 , C07D519/00 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107 , C07D519/00
Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US10087179B2
公开(公告)日：2018-10-02
申请号：US15101767
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Gareth Neil Brace , Julien Alistair Brown , Mark Daniel Calmiano , Prafulkumar Tulshibhai Chovatia , Michael Deligny , Ellen Olivia Gallimore , Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Malcolm MacCoss , Joanna Rachel Quincey , Yogesh Anil Sabnis , Dominique Louis Léon Swinnen , Zhaoning Zhu , Uwe Heinelt , Volkmar Wehner
IPC: C07D471/04 , C07D519/00 , A61K31/437
Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09873703B2
公开(公告)日：2018-01-23
申请号：US15038733
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Martin Clive Hutchings , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/5025 , A61K31/506 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09714251B2
公开(公告)日：2017-07-25
申请号：US15038818
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , John Robert Porter , Joanna Rachel Quincey
IPC: C07D487/04 , C07D403/04 , C07D403/12 , C07D403/14 , C07D401/04 , C07D401/12 , C07D401/14 , A61K31/53 , A61P19/02
CPC classification number: C07D487/04 , A61K31/53 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14
Abstract: A series of substituted imidazo[1,2-b][1,2,4]triazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.031 seconds)
